TrialMovement disorders : official journal of the Movement Disorder Society2025

NLX-112 Randomized Phase 2A Trial: Safety, Tolerability, Anti-Dyskinetic, and Anti-Parkinsonian Efficacy.

Per Svenningsson et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.